Bayer profits up 11.5 percent on new drugs

April 25, 2013

German chemical and pharmaceutical company Bayer AG said Thursday that its net profit rose 11.5 percent in the first quarter as new drugs, led by blood thinner Xarelto, boosted sales.

The company also saw stronger demand in emerging markets—which helped overcome weaker business in Europe, which is in a recession.

Overall, Bayer said its net income rose to 1.16 billion euros ($1.51 billion) from 1.04 billion in the same quarter a year earlier and that revenue rose 2.1 percent to 10.2 billion euros.

The standout performance was Xarelto, which more than tripled sales to 155 million euros. The drug's uses include preventing potentially life threatening blood clots that can form in people who have had hip or .

The company said it also had strong results from cancer drug Stivarga and from Eylea, which is used to treat the eye disease macular degeneration.

Elsewhere, Bayer said health care sales rose 7.6 percent in Asia and 4.5 percent in North America, outpacing Europe at 1.9 percent.

The company also saw continuing strong demand for its farm products such as seeds and crop protection chemicals, and that despite a late start to the growing season in the . That division raised its sales by 5.9 percent thanks to persistently high price levels for agricultural commodities.

The company stood by its forecast for a high-single digit percentage increase in profits and an increase in sales of between 4 percent and 5 percent.

Explore further: SAP says profits up in first quarter

shares

Related Stories

SAP says profits up in first quarter

April 13, 2012

German software giant SAP said on Friday it was sticking to its full-year targets for 2012 after profits rose in the first three months.

SAP says earnings up 18% in second quarter

July 24, 2012

German software giant SAP said Tuesday that bottom-line profits grew sharply in the second quarter of this year as software sales topped record levels.

Amadeus quarterly profit soars 30 percent

August 3, 2012

Spain's Amadeus, the world's biggest processor of travel bookings, on Friday announced second-quarter net profits of 164.6 million euros ($200.9 million), up 30.3 percent on the same period last year.

Merck Q4 net profit more than doubles

March 7, 2013

Merck KGaA saw its profit more than double in the fourth quarter as the German pharmaceutical company benefited from higher prices for its Rebif multiple sclerosis drug and reaped rewards from its ongoing restructuring.

Roche sales up 5 percent amid rush for Tamiflu, cancer drugs

April 11, 2013

Swiss drug giant Roche said Thursday that heightened demand for its Tamiflu drug amid a severe flu season, as well as for its cancer medicines had sent its first-quarter sales up five percent, beating analyst expectations.

Recommended for you

Non-addictive painkiller shows promise in animal trials

August 30, 2016

(HealthDay)—Preliminary research in monkeys suggests that a new medication might be able to provide pain relief similar to opioid drugs such as OxyContin, but without the same potential for addiction or serious side effects.

Mylan launching cheaper, generic version of EpiPen

August 29, 2016

The maker of EpiPens will start selling a cheaper, generic version of the emergency allergy shots as the furor over repeated U.S. price hikes continues—and looming competition threatens its near-monopoly.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.